Medera Receives FDA Fast Track Designation for Gene Therapy Targeting Duchenne Muscular Dystrophy-Associated Cardiomyopathy

Medera Inc. ("Medera"), a clinical-stage biopharmaceutical company developing next-generation cardiovascular therapeutics, and its clinical development division Sardocor, today announced that the U.S.

MeiraGTx rises on upcoming Phase 1 readout for gene therapy

MeiraGTx (MGTX) stock jumps as the company plans to disclose long-term data from a Phase 1 trial for its gene therapy ...

VectorBuilder Introduces High-Stability MuteFree™ AAV to Improve Gene Therapy Manufacturing Reliability

VectorBuilder, a global leader in gene delivery technologies and CDMO solutions, today announced MuteFree™ AAV, a ...

Gene Therapy Market Report 2026-2034 - CRISPR and AAV Technologies Propel Gene Therapy Advancements; Global Market Growing at 12.27% CAGR

The global gene therapy market size is projected to expand significantly, with an estimated value of USD 19.3 billion by 2034 ...

OXB launches fast-track offering for AAV and lentiviral vector platforms, accelerating viral vector development and manufacture

New expedited service line designed for biotechs with timeline constraints, launched in response to client demandCan accelerate timeline to GMP ...

How one gene therapy is helping some deaf patients hear for the first time

A single gene therapy injection has shown the ability to restore hearing in patients with a specific genetic mutation, with ...
MedPage Today

Hemophilia B Gene Therapy Sustains Efficacy Over a Decade Later

At a median 13 years after a single infusion of AAV-mediated gene therapy, factor IX expression remained stable in 10 patients with severe hemophilia B. The median annualized bleeding rate decreased ...
Morningstar

Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy Announce License Agreement for the Development of a Gene Therapy Using TfR1 CapX, an AAV Capsid Designed to Target ...

— Finding Hope for FRRS1L plans to initiate clinical trial using TfR1 CapX gene therapy in the second half of 2026, pending regulatory review — FORT COLLINS, Colo. and NEW YORK, Feb. 18, 2026 ...
Morning Overview on MSN

Compact CRISPR tool boosts in-body gene editing to 90% in lab tests

For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...